Ratings MorphoSys AG Deutsche Boerse AG

Equities

MOR

DE0006632003

Market Closed - Deutsche Boerse AG Other stock markets 02:45:26 01/07/2024 pm IST			5-day change	1st Jan Change
67.6 ^EUR	0.00%		+0.22%	+93.70%

26/06	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
24/06	INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	DP

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+93.70%	272.8Cr	-
MODERNA, INC.	+16.59%	4.55TCr	B-
IQVIA HOLDINGS INC.	-9.89%	3.85TCr	B
LONZA GROUP AG	+38.08%	3.81TCr	A
ALNYLAM PHARMACEUTICALS, INC.	+27.12%	3.07TCr	B
CELLTRION, INC.	-8.64%	2.6TCr	C
ICON PUBLIC LIMITED COMPANY	+11.81%	2.59TCr	B-
UNITED THERAPEUTICS CORPORATION	+45.08%	1.41TCr	B+
MEDPACE HOLDINGS, INC.	+32.85%	1.27TCr	C+
BIO-TECHNE CORPORATION	-7.19%	1.13TCr	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes